Sign Up For Updates
Sign up for updates
Join our mailing list to receive updates from the Drug Pricing Lab.
Thank you for signing up to receive news and information from the Drug Pricing Lab.
Return to Previous Page
Impact of President Trump's proposed 340B hospital eligibility threshold
Research tells us 9% of hospitals would lose their 340B eligibility under Trump's drug pricing plan. Essentially all are in Medicaid expansion states.
Nikpay, Bach, Conti
May 11, 2018
60 Minutes: The Rockford File
Dr. Bach contributed to The Rockford File segment following one drug, HP Acthar, that threatened to financially cripple the city of Rockford, Illinois.
May 10, 2018
Value-based pricing concepts laid out
Costs of Care
In a JAMA Viewpoint, DPL’s Anna Kaltenboeck and Dr. Peter Bach offer a taxonomy of the features that make a payment model truly value-based.
Journal of American Medical Association
May 2, 2018
DPL, Commonwealth Fund and Health Affairs release policy papers
Culminating a collaboration with the Drug Pricing Lab and The Commonwealth Fund, Health Affairs has released the final three policy papers.
March 21, 2018
TEDMED Talk: Changing the drug pricing game with Dr. Peter Bach
Dr. Bach explained in human terms the consequences of and proposed solutions to rising prescription drug costs at TEDMED's annual event.
March 15, 2018
DPL Policy Tracker Collects Drug Pricing Legislation and Proposals
The Drug Pricing Lab launches its DPL Policy Tracker, a regularly updated tool that is featured in The New York Times, which pulls together 181 drug pricing policy proposals.
New York Times
September 25, 2017
DPL Responds to CMS Proposed Changes to OPPS Policy
The Drug Pricing Lab submits a response to CMS-1678-P proposed changes to the Hospital Outpatient Prospective Payment Policy (OPPS).
Drug Pricing Lab
September 15, 2017
Indication Specific Pricing as a Pathway for Value Based Pricing
DrugPricingLab op-ed in StatNews discusses indication-specific pricing of Kymriah
August 31, 2017
With Conservative Assumptions US Drug Prices Still In Excess of R&D Costs
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog
August 1, 2017
Baseball Illuminates the Problem with US Drug Pricing
Dana Goldman and Darius Lakdawalla look to Major League baseball to explain the drug pricing problem.
Drug Pricing Lab
July 26, 2017
DPL and collaborators to publish drug pricing primer series
DPL and Commonwealth Fund are partnering with Health Affairs to create a series of educational primers on key topics in US drug pricing.
Health Affairs, Drug Pricing Lab, Commonwealth Fund
July 24, 2017
Is outcomes-based contracting worth it?
Katie Thomas and Charles Ornstein examine the costs and benefits of outcomes-based contracting
New York Times and ProPublica
July 12, 2017
No Results Found